Separation matrix

Patent metadata

Field	Value
Publication number	US-10711035-B2
Application number	US-201916682855-A
Country	US
Kind code	B2
Filing date	Nov 13, 2019
Priority date	May 11, 2016
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein:
a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

First claim

The invention claimed is:

1. A separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein:
a) said ligands comprise multimers of alkali-stabilized Protein A domains, and
b) said porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml,
wherein the separation matrix has a 10% breakthrough dynamic binding capacity for IgG of at least 45 mg/ml at 2.4 min residence time.

2. The separation matrix of claim 1 , wherein said cross-linked polymer particles comprise cross-linked polysaccharide particles.

3. The separation matrix of claim 1 , wherein said cross-linked polymer particles comprise cross-linked agarose particles.

4. The separation matrix of claim 1 , wherein said cross-linked polymer particles have a pore size corresponding to an inverse gel filtration chromatography Kd value of 0.69-0.85 for dextran of Mw 110 kDa.

5. The separation matrix of claim 1 , wherein said multimers comprise tetramers, pentamers, hexamers or heptamers of alkali-stabilized Protein A domains.

6. The separation matrix of claim 1 , wherein said multimers comprise hexamers of alkali-stabilized Protein A domains.

7. The separation matrix of claim 1 , having a max pressure of at least 0.58 MPa when packed at 300+/−10 mm bed height in a 35 mm separation column.

8. The separation matrix of claim 1 , having a 10% breakthrough dynamic binding capacity for IgG of at least 60 mg/ml at 6 min residence time.

9. The separation matrix of claim 1 , wherein the 10% breakthrough dynamic binding capacity for IgG at 2.4 min residence time is reduced by less than 20% after incubation 31 h in 1.0 M aqueous NaOH at 22+/−2 C.

10. The separation matrix of claim 1 , having a dissociation constant for IgG2 of below 0.2 mg/ml in 20 mM phosphate buffer, 180 mM NaCl, pH 7.5.

11. The separation matrix of claim 1 , wherein said alkali-stabilized Protein A domains comprise an Fc-binding polypeptide having an amino acid sequence as defined by, or having at least 80% identity to SEQ ID NO:53 and

(SEQ ID NO 53)

X 1 Q X 2 AFYEILX 3 LP NLTEEQRX 4 X 5 F IX 6 X 7 LKDX8PSX 9

SX 10 X 11 X 12 LAEAKX 13  X 14 NX 15 AQ

wherein individually of each other:
X 1 =A or Q or is deleted
X 2 =E, K, Y, T, F, L, W, I, M, V, A, H or R
X 3 =H or K
X 4 =A or N
X 5 =A, G, S, Y, Q, T, N, F, L, W, I, M, V, D, E, H, R or K
X 6 =Q or E
X 7 =S or K
X 8 =E or D
X 9 =Q or V or is deleted
X 10 =K, R or A or is deleted
X 11 =A, E or N or is deleted
X 12 =I or L
X 13 =K or R
X 14 =L or Y
X 15 =D, F, Y, W, K or R.

12. The separation matrix of claim 11 , wherein individually of each other:
X 1 =A or is deleted, X 2 =E, X 3 =H, X 4 =N, X 6 =Q, X 7 =S, X 8 =D, X 9 =V or is deleted, X 10 =K or is deleted, X 11 =A or is deleted, X 12 =I, X 13 =K, X 14 =L.

13. The separation matrix of claim 11 , wherein said multimers comprise hexamers of alkali-stabilized Protein A domains.

14. The separation matrix of claim 1 , wherein the polypeptides are linked by linkers comprising up to 25 amino acids.

15. The separation matrix of claim 1 , wherein at least two polypeptides are linked by linkers comprising or consisting essentially of a sequence having at least 90% identity with an amino acid sequence selected from the group consisting of APKVDAKFDKE (SEQ ID NO:96, APKVDNKFNKE (SEQ ID NO:97), APKADNKFNKE (SEQ ID NO:98), APKVFDKE (SEQ ID NO:99), APAKFDKE (SEQ ID NO:100), AKFDKE (SEQ ID NO:101), APKVDA (SEQ ID NO:102), VDAKFDKE (SEQ ID NO:103), APKKFDKE (SEQ ID NO:104), APK, APKYEDGVDAKFDKE (SEQ ID NO:105) and YEDG (SEQ ID NO:106).

16. A method of isolating an immunoglobulin, comprising the steps of:
a) contacting a liquid sample comprising an immunoglobulin with a separation matrix according to claim 1 ,
b) washing said separation matrix with a washing liquid,
c) eluting the immunoglobulin from the separation matrix with an elution liquid, and
d) cleaning the separation matrix with a cleaning liquid.

17. The method of claim 16 , wherein the cleaning liquid comprises 0.1-1.0 M NaOH or KOH.

18. The method of claim 16 , wherein steps a)-d) are repeated at least 10 times.

19. The separation matrix of claim 1 , comprising at least 15-21 mg/ml Fc-binding ligands covalently coupled to the porous support.

20. The separation matrix of claim 1 , comprising at least 17-21 mg/ml Fc-binding ligands covalently coupled to the porous support.

21. The separation matrix of claim 1 , comprising at least 18-20 mg/ml Fc-binding ligands covalently coupled to the porous support.

22. The separation matrix of claim 1 , having a 10% breakthrough dynamic binding capacity for IgG of at least 50 mg/ml at 2.4 min residence time.

23. The separation matrix of claim 1 having a 10% breakthrough dynamic binding capacity for IgG of at least 55 mg/ml at 2.4 min residence time.

24. The separation matrix of claim 1 , having a 10% breakthrough dynamic binding capacity for IgG of at least 65 mg/ml at 6 min residence time.

25. The separation matrix of claim 1 , having a 10% breakthrough dynamic binding capacity for IgG of at least 70 mg/ml at 6 min residence time.

26. The separation matrix of claim 1 , having a 10% breakthrough dynamic binding capacity for IgG of at least 75 mg/ml at 6 min residence time.

27. The separation matrix of claim 1 , having a dissociation constant for IgG2 of below 0.1 mg/ml in 20 mM phosphate buffer, 180 mM NaCl, pH 7.5.

28. The separation matrix of claim 11 , wherein the amino acid sequence has at least 90% identity to SEQ ID NO:53.

29. The separation matrix of claim 11 , wherein the amino acid sequence has at least 95% identity to SEQ ID NO:53.

30. The separation matrix of claim 11 , wherein the amino acid sequence has at least 98% identity to SEQ ID NO:53.

31. The separation matrix of claim 11 , wherein the amino acid sequence is identical to SEQ ID NO:53.

Assignees

• Ge Healthcare Bioprocess R&D Ab

Inventors

• Rodrigo Gustav José
• Bjorkman Tomas
• Ander Mats
• Hansson Jesper Ulf

Classifications

• C07K14/31

  from Staphylococcus (G) · CPC title

• B01J20/24

  Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives · CPC title

• C07K17/10

  the carrier being a carbohydrate · CPC title

• C07K16/065

  Purification, fragmentation · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title